Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Peking University First Hospital
1\) No lymph node metastasis Choose SBRT radiotherapy as much as possible Tumour PTV 50Gy/10f; if the tumour is close to the intestine, the radiotherapy dose can be appropriately reduced 40-50Gy/8-10f; to ensure intestinal safety 2)With regional lymph node metastasis Renal pelvis tumour: tumour PGTV 62.5Gy/25f; for tumour larger than 3cm P-SBRT radiotherapy is feasible, SBRT 18-24Gy/3-4f; Affected kidney + para-abdominal aorta + common iliac lymph node drainage area 47.5Gy/25f; metastatic lymph nodes 62.5Gy/25f. 3\) Routinely segmented normal tissue limits are as follows: Contralateral kidney V20\<15% Dmean 15Gy Duodenum Dmax\<50Gy Jejunum/ileum/colon V50\<5% Dmax\<52Gy Spinal cord Damx \<40Gy Liver At least 700cc volume should receive a dose \<25Gy SBRT segmentation Normal tissue limits are as follows: Duodenum Dmax\<32Gy; V18\<5cc Jejunum/ileum/colon Dmax\<35Gy; V19.5\<5cc Stomach Dmax\<32Gy; V18\<5cc (4) Short-term efficacy judgement: 1 month after radiotherapy to review imaging, short-term efficacy based on RECIST1.1 criteria, partial remission (PR partial regression) or complete remission (CR complete regression); disease-free survival is defined as the period after treatment to the emergence of recurrence in the radiotherapy field, intra-urethral recurrence (except bladder recurrence) or Regional lymph node metastases at first recurrence.
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
